Merck Animal Health Makes Minority Investment in LeeO Precision Agriculture

September 27, 2022 7:00 a.m. ET

Digital pig traceability solution tracks pigs throughout their life cycle

Investment complements Merck Animal Health‘s broad portfolio of veterinary pharmaceuticals, vaccines and technology solutions

MADISON, NJ, September 27, 2022 – Merck Animal Health, known as MSD Animal Health outside the United States and Canada, a division of Merck & Co., Inc., Rahway, NJ, USA (NYSE: MRK ), announced today that it has made a minority investment in LeeO Precision Farming BV (LeeO). Merck Animal Health will also assume the distribution of LeeO’s digital swine traceability solution in selected markets over the coming months. Merck Animal Health joins existing founders and shareholders of LeeO, Prairie Systems, Inc., a strategic investment of United Animal Health, Inc., and MIQ BV The specific terms of the minority investment were not disclosed.

LeeO, a private company located in Deventer, the Netherlands, provides a real-time cloud-based digital pig traceability solution for farmers, producers and retailers to continuously track and analyze pigs from birth throughout their life cycle. The cloud-based technology platform provides users with the ability to record and track key life events in pig production, including genetics, insemination, birth registration, vaccination, l age, weight, weaning, location and transport. The platform is supported by an ecosystem of RFID-based hardware technologies, such as ear tags, readers and scales.

“Through this agreement, we connect the breadth and depth of Merck Animal Health’s animal health intelligence technology solutions to LeeO’s innovative digital swine traceability platform, which can help change the way all phases of pig production interact and make decisions,” said Jeroen van de Ven, Manager, Animal Health Intelligence, Merck Animal Health. “Our animal health solutions, including our identification, traceability and monitoring capabilities, and the investment in LeeO will help accelerate the development of this technology and advance animal health and welfare. We look forward to our partnership with LeeO and continuing to build the future of livestock traceability solutions, which can further create a connected and integrated ecosystem for the global livestock market.

LeeO CEO Peter ter Linde said, “This investment from Merck Animal Health is an exciting development for LeeO and will be used to fuel our growth and investment in our leading digital animal traceability solution for pigs. It also signals Merck Animal Health’s continued commitment to swine health, welfare and management and its focus on accelerating animal traceability solutions in livestock to improve animal health. We are confident that Merck Animal Health’s investment will further accelerate the growth and value of our business. »

“The addition of Merck Animal Health to LeeO ownership will certainly allow for faster growth, which is great for the swine industry,” said Doug Webel, Ph.D., President and CEO of United Animal. Health, Inc., a strategic partner of LeeO for food chain visibility and analytics. “We see this agreement as a key step to advance this technology and animal traceability for better animal health.”

Evidence-based animal traceability solutions have helped preserve and strengthen the integrity of the food supply chain. Traceability solutions, such as LeeO’s digital traceability platform, provide customers with information that identifies and traces the origin, history, production and distribution throughout the pork lifecycle to validate claims of sustainability by detailing how the animals are raised and processed.

About Merck Animal Health

At Merck, known as MSD outside the United States and Canada, we are united around our purpose: We use the power of cutting-edge science to save and improve lives around the world. For more than a century, we’ve been at the forefront of research, delivering innovative medicines, vaccines and healthcare solutions for the world’s most challenging diseases. Merck Animal Health, a division of Merck & Co., Inc., Rahway, NJ, USA, is the global animal health business of Merck. Through its commitment to The Science of Healthier Animals®, Merck Animal Health offers veterinarians, breeders, pet owners and governments one of the widest ranges of veterinary pharmaceuticals, vaccines and veterinary solutions and services. health management, as well as a full suite of connected technologies that includes identification, traceability and control products. Merck Animal Health is dedicated to preserving and improving the health, welfare and performance of animals and the people who care for them. It invests heavily in dynamic and comprehensive R&D resources and a modern global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit and connect with us on LinkedIn, Facebook, Twitterand Instagram.

Merck & Co., Inc., Rahway, NJ, USA Forward-Looking Statement

This press release from Merck & Co., Inc., Rahway, NJ, USA (the “Company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995 These statements are based on the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include, but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and around the world; global trends toward health care cost containment; technological advances, new products and patents obtained by competitors; challenges inherent in developing new products, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and exposure to litigation, including patent litigation, and/or regulatory actions.

The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Other factors that could cause results to differ materially from those described in the forward-looking statements can be found in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and other company filings. with the Securities and Exchange Commission. (SEC) available on the SEC’s website (

Media contacts:

Gail S. Thornton

(908) 392-3420

[email protected]

Noreen Verbrugge

(973) 937-5450

[email protected]

Investor contacts:

Pierre Dannenbaum

(908) 740-1047

[email protected]

Boyd S. Abbott